4:16 PM
 | 
May 15, 2018
 |  BC Extra  |  Company News

FDA approves Pfizer's Retacrit, first epoetin alfa biosimilar in U.S.

FDA approved Retacrit epoetin alfa-epbx from Pfizer Inc. (NYSE:PFE), a biosimilar of anemia drugs Epogen from Amgen Inc. (NASDAQ:AMGN) and Procrit from the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ). FDA said it is the first approved biosimilar of epoetin alfa, an agonist of the erythropoietin (EPO) receptor, in the U.S.

Pfizer said the approval covers all of Retacrit's reference...

Read the full 289 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >